Improved endpoints for cancer immunotherapy trials

Journal of the National Cancer Institute

Volumn 102, Issue 18, 2010, Pages 1388-1397

  Hoos, Axel ^a,b   Eggermont, Alexander M M ^c   Janetzki, Sylvia ^a,d   Hodi, F Stephen ^e   Ibrahim, Ramy ^a,b   Anderson, Aparna ^b   Humphrey, Rachel ^b   Blumenstein, Brent ^f   Old, Lloyd ^a,g   Wolchok, Jedd ^a,h  

^a CIC CRI   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Zellnet Consulting   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f TriArc Consulting   (United States)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; CANCER VACCINE; TUMOR MARKER;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; TUMOR IMMUNITY; TUMOR VOLUME; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY (TOPIC); NEOPLASMS; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; TIME; TREATMENT OUTCOME; TRENDS;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957273591     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq310     Document Type: Review

References (55)

1. Finke LH, Wentworth K, Blumenstein B, et al. Lessons from randomized phase III studies with active cancer immunotherapies\outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 2007; 25(suppl 2):B97-B109.
2. Copier J, Dalgleish AG, Britten CM, et al. Improving the effcacy of cancer immunotherapy. Eur J Cancer. 2009;45(8):1424-1431.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-915.
4. Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704-2715.
5. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95-106.
6. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206-213.
7. Ribas A, Butterfeld LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21(12):2415-2432.
8. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30(1):1-15.
9. Hoos A. Proposal of a clinical development paradigm for cancer immuno-therapy: novel endpoints. In: Endpoints for Immunotherapy Studies: Design and Regulatory Implications, American Society of Clinical Oncology (ASCO) Annual Meeting; June 2, 2008; Chicago, IL.
10. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Reviews Cancer. 2006;6(5):409-414.
11. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Reviews Cancer. 2009;9(9):675-681.
12. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-3094.
13. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer [published online ahead of print January 25, 2010]. J Clin Oncol. 2010;28(7):1085-1087.
14. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer [published online ahead of print January 25, 2010]. J Clin Oncol. 2010;28(7):1099-1105.
15. Hamid O, Urba WJ, Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma [abstract 8525]. J Clin Oncol. 2007;25(suppl):18s.
16. Wolchok JD, Ibrahim R, DePril V, et al. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment [abstract 3020]. J Clin Oncol. 2008;26(suppl):19s.
17. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2): 155-164.
18. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical beneft associated with idiotype vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98(18):1292-1301.
19. Longo DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J Natl Cancer Inst. 2006;98(18):1263-1265.
20. Janetzki S, Panageas KS, Ben-Porat L, et al.; for the Elispot Profciency Panel of the CVC Immune Assay Working Group 2007. Results and Harmonization Guidelines from two large-scale international Elispot profciency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008;57(3):303-315.
21. Britten CM, Gouttefangeas C, Schoenmaekers-Welters MJP, et al. The CIMT-Monitoring panel: a two-step approach to harmonize the enumeration of antigen-specifc CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother. 2008;57(3):303-315.
22. Britten CM, Janetzki S, Ben-Porat L, et al.; for the HLA-peptide Multimer Profciency Panel of the CVC-CRI Immune Assay Working Group. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international profciency panel of the Cancer Vaccine Consortium (CVC). Cancer Immunol Immunother. 2009;58(10):1701-1713
23. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2009. http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/default.htm.
24. Maecker HT. The role of immune monitoring in evaluating cancer immu-notherapy. In: Disis ML, eds. Cancer Drug Discovery and Development: Immunotherapy of Cancer.Totowa, NJ: Humana Press; 2005:59-72.
25. Hobeika AC, Morse MA, Osada T, et al. Enumerating antigen-specifc T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother. 2005;28(1):63-72.
26. Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol. 2003;22(3-4):283-319.
27. Keilholz U, Weber J, Finke LH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002;25(2):97-138.
28. Janetzki S, Britten CM, Kalos M, et al. MIATA\minimal information about T cell assays. Immunity. 2009;31(4):527-528.
29. Tuomela M, Stanescu I, Krohn K. Validation overview of bio-analytical methods. Gene Ther. 2005;12(suppl 1):S131-S138.
30. Britten CM, Janetzki S, van der Burg SH, et al. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother. 2008;57(3):285-288.
31. International Conference on Harmonization (ICH). Guidance for Industry: Good Clinical Practice. 1997;62(90):25691-25709E7
32. NCCLS. Evaluation of Matrix Effects, Approved Guidelines. NCCLS document EP14-A [ISBN 1-56238-434-1]. Wayne, PA: NCCLS.
33. Janetzki S, Price L, Britten CM, et al. Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother. 2010;59(4):609-618.
34. WHO Handbook for Reporting Results of Cancer Treatment.Geneva, Switzerland: World Health Organization Offset Publication No. 48; 1979.
35. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3): 205-216.
36. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
37. Berd D, Sato T, Cohn H, et al. Treatment of metastatic melanoma with autologous, hapten-modifed melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001;94(4):531-539.
38. Kruit WHJ, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005;117(4):596-604.
39. van Baren N, Bonnet MC, Dréno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23(35): 9008-9021.
40. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci\USA. 2008;105(8):3005-3010.
41. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and effcacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591-5598.
42. O'Day S, Ibrahim R, DePril V, et al. Effcacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies [abstract 9021]. Proc Am Soc Clin Onc. 2008;26(20 suppl).
43. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
44. Hodi FS, Hoos A, Ibrahim R, et al. Novel effcacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, and anti-CTLA-4 monoclonal antibody [abstract 3008]. J Clin Oncol. 2008;26(suppl):19s.
45. Tuma RS. New response criteria proposed for immunotherapies. J Natl Cancer Inst. 2008;100(18):1280-1281.
46. Sosman JA, Unger JM, Liu PY, et al.; Southwest Oncology Group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002;20(8):2067-2075.
47. Testori A, Richards J, Whitman E, et al.; for the C-100-21 Study Group. Comparison of autologous tumor-derived heat shock protein gp96-peptide complexes (vitespen) and physician's choice in a randomized phase 3 trial in patients with stage IV melanoma. J Clin Oncol. 2008;26(6):955-962.
48. Wood C, Srivastava P, Bukowski R, et al.; for the C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after ne-phrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-154.
49. Hodi FS, O'Day S, McDermott DF, et al. Improved survival with ipilim-umab in patients with metastatic melanoma [published online ahead of print June 14, 2010]. N Engl J Med. 2010doi:10.1056/NEJMoa1003466.
50. Fine GD. Consequences of delayed treatment effects on analysis of time-to-event endpoints. Drug Inf J. 2007;41:535-539.
51. Fleming TR, Harrington DP. Counting Processes and Survival Analysis.New York, NY: John Wiley & Sons; 1991.
52. Lakatos E. Sample size based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44(1):229-241.
53. Sposto R, Stablein D, Carter-Campbell S. A partially grouped logrank test. Stat Med. 1997;16(6):695-704.
54. Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(19):1455-1461.
55. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces signifcant clinical beneft in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5(9):557-561.